Allarity Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $22.6M
- Price
- $1.42
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.70%
- Volume
- 112.3K
About
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Quick stats
Shares outstanding15.9M
Computed float15.8M
Float / shares99.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001860657
Websitehttps://www.allarity.com
AI Summary
AI-generated1/16
majorbullishearnings
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
Allarity completed its Phase 3-ready manufacturing campaign for stenoparib ahead of schedule and secured CLIA certification for its in-house laboratory, significantly de-risking its path toward a pivotal trial.
The USPTO granted a key patent covering the stenoparib DRP companion diagnostic, extending commercial exclusivity protection into April 2042.
Financially, the company ended the quarter with $26.9 million in cash and restricted cash, nearly double the prior year’s balance, while reporting a net loss of $3.4 million.